The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

A Belfast company Re-Vana Therapeutics – a spin-out from Queen’s University – has signed a major collaboration deal that could be worth more than $1bn.

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Queen’s University Belfast spin-out company Re-Vana Therapeutics has signed a landmark collaboration deal with German ...

The global canine arthritis treatment market is set for substantial expansion, projected to grow from an estimated USD 2.50 ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...